NPPB and hydrops fetalis: The PARALLEL-HF trial done in the Japanese cohort demonstrated that patients in the sacubitril/valsartan and enalapril groups experienced reductions in plasma NT-proBNP levels of 21.3% and 22.9%, respectively, after receiving treatment with 50 mg of sacubitril/valsartan twice daily for two weeks during the run-in phase.